Rock Springs Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Rock Springs Capital Management’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-162,750	Closed	-$6.55M	–	107
2026 Q1	$6.55M	Buy	162,750 +12,250	+8%	+$264K	0.39%	59
2025 Q4	$3.78M	Buy	150,500 +58,500	+64%	+$1.37M	0.19%	82
2025 Q3	$2.08M	Buy	92,000 +7,700	+9%	+$180K	0.12%	77
2025 Q2	$1.46M	Buy	84,300 +4,300	+5%	+$79.6K	0.09%	82
2025 Q1	$1.75M	Hold	80,000	–	–	0.1%	80
2024 Q4	$2.55M	Hold	80,000	–	–	0.1%	89
2024 Q3	$2.31M	Sell	80,000 -60,700	-43%	-$2.25M	0.08%	95
2024 Q2	$5.4M	Buy	+140,700	New	+$6.37M	0.16%	83
2021 Q4	–	Sell	-26,458	Closed	-$872K	–	138
2021 Q3	$872K	Buy	+26,458	New	+$1.49M	0.02%	151

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Rock Springs Capital Management's APLS Position: Q2 2026 in Review

Rock Springs Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 162,750 shares — an estimated $6.55M sold.

Rock Springs Capital Management first reported a position in APLS in Q3 2021 and held it in 9 quarters. The position peaked at $6.55M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

Rock Springs Capital Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Rock Springs Capital Management sold 162,750 Apellis Pharmaceuticals shares in Q2 2026, an estimated $6.55M.
Rock Springs Capital Management first reported a position in Apellis Pharmaceuticals in Q3 2021 and held it in 9 quarters.
Rock Springs Capital Management's Apellis Pharmaceuticals position peaked at $6.55M in Q1 2026.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Rock Springs Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.